DDInter1731 DDInter927
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Sunitinib {u} (Compound) resembles {v} (Compound) Metoclopramide
Sunitinib {u} (Compound) treats {v} (Disease) pancreatic cancer
Sunitinib {u} (Compound) binds {v} (Gene) SBK1
Sunitinib {u} (Compound) upregulates {v} (Gene) CRIP1
Sunitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Sunitinib {u} (Compound) downregulates {v} (Gene) INTS3
Sunitinib {u} (Compound) causes {v} (Side Effect) Candida infection
Sunitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Sunitinib (Compound) resembles Metoclopramide (Compound)
Sunitinib (Compound) treats pancreatic cancer (Disease)
Sunitinib (Compound) binds SBK1 (Gene)
Sunitinib (Compound) upregulates CRIP1 (Gene)
Sunitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Sunitinib (Compound) downregulates INTS3 (Gene)
Sunitinib (Compound) causes Candida infection (Side Effect)
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline